Expert Interview
A second look: Discussing the topline data of batoclimab in Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and how it may translate to IMVT-1402.
Ticker(s): IMVT, ROIV, ARGXInstitution: Wayne State University
- Assistant Professor in Neurology and Director of the Residency training program at Wayne State University.
- Manages 500 patients with Multiple sclerosis.
- Specializes in autoimmune neurological disorders including NMOSD, MOG antibody disease, Neurosarcoidosis, Myasthenia Gravis, Chronic inflammatory demyelinating polyneuropathy (CIDP), paraneoplastic disorders, and the neurologic complications of systemic autoimmune disorders such as Lupus and Sjogren's Syndrome.
What are you currently using to treat MG?
Added By: wilson_adminWhat would a medication need to show to take market share from Vyvgart?
Added By: wilson_adminHow well do you think the data from batoclimab will translate to IMVT-1402?
Added By: wilson_adminIt looked like the baseline MG-ADL of patients in the Batoclimab data was similar to Vyvgart's ADAPT. But baseline use of steroids and NSIST's was substantially lower. Doesn't that imply that patients were less well controlled in the Batoclimab trial?
Added By: wilson_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
